EGFR and hepatocellular carcinoma: SNX16 has previously been described as acting as an oncogene in hepatocellular carcinoma, promoting tumor aggressiveness through the EGFR–AKT pathway, and its inhibition has been proposed to offer therapeutic benefits by blocking tumor cell proliferation and invasion [55].